# Nuclear prostaglandin E synthase 3 promotes hepatocellular carcinoma growth with immunosuppressive macrophage polarization via the SP1/TGF-β axis

**Authors:** Nianfei Wang, Wei Chen, Shumin Shen, Jian Qi, Shanghu Wang, Rong Wang, Ming Li, Zixiang Chen, Jiangming Chen, Bo Hong, Hongzhi Wang

PMC · DOI: 10.1186/s43556-026-00431-6 · 2026-03-25

## TL;DR

This study shows that PTGES3, a protein in the nucleus, promotes liver cancer growth and immune suppression by influencing macrophages and signaling pathways.

## Contribution

The study reveals a new nuclear role for PTGES3 in linking tumor growth and immune evasion in hepatocellular carcinoma.

## Key findings

- PTGES3 is upregulated in HCC and predicts poor survival outcomes.
- PTGES3 deficiency reduces tumor growth and alters immune cell infiltration in mice.
- PTGES3 regulates SP1 and TGF-β to drive tumor proliferation and M2 macrophage polarization.

## Abstract

Hepatocellular carcinoma (HCC) is characterized by the synchronization of tumor cell proliferation and an immunosuppressive microenvironment. Decoupling these interconnected processes represents a major therapeutic challenge. Although Prostaglandin E Synthase 3 (PTGES3) functions canonically as a cytoplasmic Heat Shock Protein 90 (HSP90) co-chaperone, its non-canonical nuclear role in orchestrating tumor-immune crosstalk remains undefined. Here, we identify PTGES3 as a dual-function regulator coupling tumor intrinsic growth with extrinsic immune remodeling. We report that PTGES3 is upregulated in HCC and serves as an independent prognostic factor for poor survival. Using an immunocompetent, diethylnitrosamine (DEN)-induced HCC mouse model, we demonstrate that hepatocyte-specific Ptges3 silencing significantly suppresses tumorigenesis. Single-cell RNA sequencing (scRNA-seq) and histological analysis reveal that PTGES3 deficiency remodels the immune landscape, specifically by impairing tumor-associated macrophage (TAM) infiltration and M2 polarization. Mechanistically, we identified a specific G-rich motif on the Specificity Protein 1 (SP1) promoter bound by PTGES3 (confirmed via electrophoretic mobility shift assay [EMSA] and Cleavage Under Targets and Tagmentation [CUT&Tag]), which drives SP1-mediated Transforming Growth Factor-β (TGF-β) secretion. This axis appears to exert dual oncogenic effects: triggering paracrine M2 macrophage polarization to foster immunosuppression, whilst simultaneously fueling an autocrine TGF-β/TGFBR/PI3K/AKT/mTOR signaling loop to sustain tumor proliferation. Our findings define a non-canonical nuclear function for PTGES3, identifying it as a critical molecular switch that couples tumor aggressiveness with microenvironmental remodeling, thus presenting a promising therapeutic target for HCC.

The online version contains supplementary material available at 10.1186/s43556-026-00431-6.

## Linked entities

- **Genes:** PTGES3 (prostaglandin E synthase 3) [NCBI Gene 10728], SP1 (Sp1 transcription factor) [NCBI Gene 6667], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], LOC135820916 (uncharacterized LOC135820916) [NCBI Gene 135820916], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475]
- **Diseases:** Hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, FOSL2 (FOS like 2, AP-1 transcription factor subunit) [NCBI Gene 2355] {aka ACED, FRA2}, PTGES (prostaglandin E synthase) [NCBI Gene 9536] {aka MGST-IV, MGST1-L1, MGST1L1, MPGES, PGES, PIG12}, PTGES3 [NCBI Gene 102641464], POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, CD14 (CD14 molecule) [NCBI Gene 929], PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, VSIR (V-set immunoregulatory receptor) [NCBI Gene 64115] {aka B7-H5, B7H5, C10orf54, DD1alpha, Dies1, GI24}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, JUND (JunD proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3727] {aka AP-1}, Hsp86-ps2 (heat shock protein 86, pseudogene 2) [NCBI Gene 111042] {aka 86kDa, Hsp86-3, Hsp90}, Ptges (prostaglandin E synthase) [NCBI Gene 64292] {aka 2410099E23Rik, D2Ertd369e, Pges, mPGES, mPGES-1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Ptges3 (prostaglandin E synthase 3) [NCBI Gene 56351] {aka 5730442A20Rik, Ptges, Tebp, cPGES, p23, sid3177}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, Sp1 (trans-acting transcription factor 1) [NCBI Gene 20683] {aka 1110003E12Rik, Sp1-1}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Serpina7 (serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7) [NCBI Gene 331535] {aka C730040N12Rik, Tbg}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PTGES3 (prostaglandin E synthase 3) [NCBI Gene 10728] {aka P23, TEBP, cPGES}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Cd163 (CD163 antigen) [NCBI Gene 93671] {aka CD163v2, CD163v3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Hsp84-3 (heat shock protein, 3) [NCBI Gene 104434] {aka 84kDa, Hsp90, hsp3}, PFKL (phosphofructokinase, liver type) [NCBI Gene 5211] {aka ATP-PFK, PFK-B, PFK-L}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CAT (catalase) [NCBI Gene 847], Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Cd14 (CD14 antigen) [NCBI Gene 12475]
- **Diseases:** prostate cancer (MESH:D011471), metastasis (MESH:D009362), cirrhosis (MESH:D005355), hepatoblastoma (MESH:D018197), lung cancer (MESH:D008175), tumorigenesis (MESH:D063646), Cancer (MESH:D009369), immunodeficient (MESH:D007153), ovarian cancer (MESH:D010051), mycoplasma (MESH:D009175), inflammatory (MESH:D007249), TNM (MESH:D008207), breast cancer (MESH:D001943), tumorigenic (MESH:D002471), HCC (MESH:D006528)
- **Chemicals:** Rapamycin (MESH:D020123), iohexol (MESH:D007472), crystal violet (MESH:D005840), penicillin (MESH:D010406), H&amp;E (MESH:D006371), Galunisertib (MESH:C557799), PBS (MESH:D007854), arachidonic acid (MESH:D016718), 17-AAG (MESH:C112765), streptomycin (MESH:D013307), PVDF (MESH:C024865), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), DMEM (-), 7-AAD (MESH:C025942), MTT (MESH:C070243), puromycin (MESH:D011691), PMA (MESH:D013755), 4',6-diamidino-2-phenylindole (MESH:C007293), SDS (MESH:D012967), PGE2 (MESH:D015232), DEN (MESH:D004052), CO2 (MESH:D002245)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Adeno-associated virus (species) [taxon 272636], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** F1012E, F1209C
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), siPTGES3-1 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_A9BB), Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), M0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13018494/full.md

---
Source: https://tomesphere.com/paper/PMC13018494